NASDAQ:NXTM NxStage Medical (NXTM) Stock Price, News & Analysis → Don’t Miss Out on the AI Gold Rush That’s Just Getting Started (From Banyan Hill Publishing) (Ad) Free NXTM Stock Alerts Notice: This company has been marked as potentially delisted and may not be actively trading. Add Compare Share Share Today's Range$29.98▼$30.0050-Day Range$30.00▼$30.0052-Week Range$23.17▼$30.00Volume2.61 million shsAverage Volume1.51 million shsMarket Capitalization$2.00 billionP/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock Analysis Get NxStage Medical alerts: Email Address Ad Banyan Hill PublishingDon’t Miss Out on the AI Gold Rush That’s Just Getting Started“Titan of Tech” Bets Big on Tiny AI Company He’s made as much as 3,250,000% in just three years on companies like Facebook, Airbnb, and PayPal… But our research shows his latest investment could be his most successful venture yet.See how you can invest alongside him About NxStage Medical Stock (NASDAQ:NXTM)NxStage Medical, Inc., a medical technology company, develops, manufactures, and markets products and services for patients suffering from chronic or acute kidney failure. Its primary product includes the System One, a portable hemodialysis system, which is used primarily for home hemodialysis and a range of dialysis therapies to deliver in the home setting. The company operates through three segments: System One, In-Center, and Services. The System One segment sells and rents the NxStage System One and PureFlow SL dialysate preparation equipment, as well as sells disposable products in the home and critical care market for the treatment of end-stage renal disease (ESRD) patients in the home or a home-like setting and in the critical care market for the treatment of hospital-based patients with acute kidney failure or fluid overload. The In-Center segment sells blood tubing sets and needles for hemodialysis primarily for the treatment of ESRD patients at dialysis centers, and needles for apheresis. The Services segment offers dialysis services to patients at NxStage Kidney Care dialysis centers. As of February 3, 2018, it had 21 centers. NxStage Medical, Inc. markets its products through direct sales to dialysis clinics and hospitals in the United States, the United Kingdom, and Canada, as well as through distributors in Europe and internationally. The company was formerly known as QB Medical, Inc. and changed its name to NxStage Medical, Inc. NxStage Medical, Inc. was founded in 1998 and is headquartered in Lawrence, Massachusetts.Read More Ad Banyan Hill PublishingDon’t Miss Out on the AI Gold Rush That’s Just Getting Started“Titan of Tech” Bets Big on Tiny AI Company He’s made as much as 3,250,000% in just three years on companies like Facebook, Airbnb, and PayPal… But our research shows his latest investment could be his most successful venture yet.See how you can invest alongside him NXTM Stock News HeadlinesJuly 21, 2023 | wsj.comNextcom Ltd.September 23, 2022 | reuters.comNXTM.TA - Nextcom Ltd. | Stock Price & Latest News | ReutersApril 23, 2024 | Banyan Hill Publishing (Ad)Don’t Miss Out on the AI Gold Rush That’s Just Getting Started“Titan of Tech” Bets Big on Tiny AI Company He’s made as much as 3,250,000% in just three years on companies like Facebook, Airbnb, and PayPal… But our research shows his latest investment could be his most successful venture yet.October 26, 2021 | finance.yahoo.comOmnicell to Buy Ateb, Expand in Adherence Tools MarketSee More Headlines Receive NXTM Stock News and Ratings via Email Sign-up to receive the latest news and ratings for NxStage Medical and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings8/07/2017Today4/22/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Electromedical Equipment Sub-IndustryHealth Care Equipment Current SymbolNASDAQ:NXTM CUSIP67072V10 CIK1333170 Webwww.nxstage.com Phone978-687-4700FaxN/AEmployeesN/AYear FoundedN/AProfitability EPS (Most Recent Fiscal Year)($0.22) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-14,470,000.00 Net Margins-1.29% Pretax MarginN/A Return on Equity-2.50% Return on Assets-1.60% Debt Debt-to-Equity RatioN/A Current Ratio3.60 Quick Ratio2.69 Sales & Book Value Annual Sales$393.94 million Price / Sales5.08 Cash Flow$0.29 per share Price / Cash Flow103.07 Book Value$3.22 per share Price / Book9.32Miscellaneous Outstanding Shares66,680,000Free FloatN/AMarket Cap$2.00 billion OptionableOptionable Beta0.25 7 Stocks to Own Before the 2024 ElectionLooking to avoid the hassle of mudslinging, volatility, and uncertainty? You'd need to be out of the market, which isn’t viable. So where should investors put their money? Find out with this report.Get This Free Report Key ExecutivesMr. Jeffrey H. Burbank (Age 56)Founder, CEO & Director Mr. Joseph E. Turk Jr. (Age 51)Pres Mr. Matthew W. Towse (Age 56)Sr. VP, CFO & Treasurer Ms. Winifred L. Swan (Age 55)Sr. VP, Gen. Counsel & Sec. Dr. Allan J. CollinsHead of Scientific Advisory Board & Chief Medical OfficerKey CompetitorsIntegerNYSE:ITGRMasimoNASDAQ:MASICONMEDNYSE:CNMDInModeNASDAQ:INMDSoleno TherapeuticsNASDAQ:SLNOView All Competitors NXTM Stock Analysis - Frequently Asked Questions How were NxStage Medical's earnings last quarter? NxStage Medical, Inc. (NASDAQ:NXTM) posted its earnings results on Monday, August, 7th. The medical device company reported ($0.03) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.03) by $0.00. The medical device company earned $92.20 million during the quarter, compared to analyst estimates of $96.47 million. NxStage Medical had a negative net margin of 1.29% and a negative trailing twelve-month return on equity of 2.50%. The firm's revenue was up .0% on a year-over-year basis. During the same period in the previous year, the firm posted ($0.03) earnings per share. What other stocks do shareholders of NxStage Medical own? Based on aggregate information from My MarketBeat watchlists, some companies that other NxStage Medical investors own include Xtrackers California Municipal Bond ETF (CA), Endologix (ELGX), BlackRock (BLK), Hawkins (HWKN), Chipotle Mexican Grill (CMG), Aegean Marine Petroleum Network (ANW), Athabasca Oil (ATH), Och-Ziff Capital Management Group (OZM), Gran Tierra Energy (GTE) and ALJ Regional (ALJJ). This page (NASDAQ:NXTM) was last updated on 4/23/2024 by MarketBeat.com Staff From Our PartnersThe Best AI Stock to Own in the World Today is Trading for Just $25Banyan Hill PublishingThe A.I. story nobody is telling you (Read ASAP)TradeSmithHealthcare Takes A Big Step Forward With The Help Of AIThe Bull Reporttop AI stock (it’s not MSFT, GOOGL, AMZN or AAPL)Traders AgencyDid You Get Your Free Bitcoin Yet?Crypto Swap Profits[Shocking] Elon Musk’s Plan To End BanksCrypto 101 MediaUrgent Alert: Biden's IRS Targeting Your Money – Act Fast to Protect It!American AlternativeForget Bitcoin. Crypto Millionaire Predicts 8,788% Gains For THISParadigm Press Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding NxStage Medical, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.